FORM PTO-1390 (Modified) (REV 11-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR
BERN-0050	09/913559

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US00/04703	22 February 2000	24 February 1999

TITLE OF INVENTION

An In Vivo and In Vitro Model for Cutaneous Photoaging and Oxidative Damage

APPLICANT(S) FOR DO/EO/US

BERNSTEIN, Eric F.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   b. ☐ has been communicated by the International Bureau.
   c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☐ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). – unexecuted
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with
20. ☐ A second copy of the published international application under 35 U.
21. ☐ A second copy of the English language translation of the internationa
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

1) Courtesy copy of International Application;
2) Copy of Written Opinion
3) Return post card

"Express Mail" Label No. **EL886701781US**
Date of Deposit **August 15, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
09/913559	PCT/US00/04703	BERN-0050

24.- The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS PTO USE ONLY
☐	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	$1000.00
☒	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	$860.00
☐	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	$710.00
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	$690.00
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =	$860.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	$0.00	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	6 - 20 =	0	x $18.00	$0.00	
Independent claims	1 - 3 =	0	x $80.00	$0.00	
Multiple Dependent Claims **(check if applicable)**.			☐	$0.00	

TOTAL OF ABOVE CALCULATIONS =	$860.00	
☒ Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.	$430.00	
SUBTOTAL =	$430.00	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +	$0.00	
TOTAL NATIONAL FEE =	$430.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☐	$0.00	
TOTAL FEES ENCLOSED =	$430.00	
	Amount to be: refunded	$
	charged	$

a. ☐ A check in the amount of _____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. **50-1619** in the amount of **$430.00** to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-1619** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Reg. No. 32,257
Kathleen A. Tyrrell, Reg. No. 38,350
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

Telephone: (856) 810-1515
Facsimile : (856) 810-1454



SIGNATURE

Kathleen A. Tyrrell
NAME

38,350
REGISTRATION NUMBER

August 15, 2001
DATE

AN *IN VIVO* AND *IN VITRO* MODEL FOR CUTANEOUS PHOTOAGING AND OXIDATIVE DAMAGE

Background of the Invention

Chronic sun exposure eventuates in wrinkling, sagging, pigmentary alterations, and skin cancers which are characteristic of sun-damaged skin, and collectively referred to as photoaging (Kligman, A. M., *JAMA*, 1969, 210:2377-2380; Gilchrest, B.A., *J. Am. Acad. Dermatol.*, 1989, 21:610-613,). The major histopathologic alteration of photoaged skin is the accumulation of material which, on routine histopathologic examination, has the staining characteristics of elastin and is, thus, termed solar elastosis. Immunohistochemical staining has shown the poorly-formed fibers comprising solar elastosis to be composed of elastin (Chen et al., *J. Invest. Dermatol.*, 1986, 87:334-337; Mera et al., *Br. J. Dermatol.*, 1987, 117:21-27) fibrillin (Chen et al., *J. Invest. Dermatol.*, 1986, 87:334-337; Dahlback et al., *J. Invest. Dermatol.*, 1990, 94:284-291,; Bernstein et al., *J. Invest. Dermatol.*, 1994, 103:182-186) and versican, the normal components of elastic fibers (Zimmerman et al., *J. Cell. Biol.*, 1994, 124:817-825). A coordinate increase in elastin, fibrillin and versican mRNAs has been demonstrated in fibroblasts derived from photodamaged skin, as compared to fibroblasts derived from normal skin from the same individuals (Bernstein et al., *J. Invest. Dermatol.*, 1994, 103:182-186). Elevated elastin mRNA levels in sun-damaged skin result from enhanced elastin promoter activity, as shown by transient transfections of fibroblasts with a DNA construct composed of the human elastin promoter linked to the chloramphenicol acetyltransferase (CAT) reporter gene (Bernstein et al., *J. Invest. Dermatol.*, 1994, 103:182-186).

A transgenic mouse line expressing the 5.2 kb human elastin promoter linked to a chloramphenicol acetyltransferase reporter gene (CAT) has been developed which models cutaneous

photoaging (Bernstein et al., *J. Invest. Dermatol.*, 1995, 105, 269-273). Although phenotypically normal, the cells in these mice possess the human elastin promoter/CAT construct, allowing elastin promoter activity to be measured in response to stimuli such as ultraviolet radiation (UV). Four or five day old mice which have not yet developed hair, and fibroblast cultures derived from their skin, have been demonstrated to provide a rapid and sensitive means of identifying compounds capable of inhibiting cutaneous photodamage (Bernstein et al., *J. Invest. Dermatol.*, 1995, 105, 269-273; Bernstein et al., *Photochem. Photobiol.*, 1996, 64:369-74; Bernstein et al., *J. Am. Acad. Dermatol.*, 1997, 37:725-729).

UV from the sun also damages skin by the generation of reactive oxygen species (Miyachi, Y. J., *Dermatol. Sci.*, 1995, 9:79-86). Reactive oxygen species may form immediately as a result of UV exposure, or result from the inflammatory response which often follows UV-induced injury. Although the erythema of a sunburn is clinical evidence of damage from UV, an inflammatory infiltrate may be evident histopathologically even in the absence of erythema, and may result in continued exposure of the dermis to free radicals, days after the UV-induced damage has occurred (Kligman, A. M., *JAMA*, 1969, 210:2377-2380; Lavker et al., *J. Am. Acad. Dermatol.*, 1995, 32:53-62). The role of free radicals in cutaneous photodamage has been well documented (Ranadive, N.S. and Menon, I.A., *Pathol. Immunopathol. Res.*, 1986, 5:118-139; Miyachi, Y and Imamura, S., *Photodermatol. Photoimmunol. Photomed.*, 1990, 7:49-50; Miyachi, Y. J., *Dermatol. Sci.*, 1995, 9:79-86; and Peak et al., *Photochem. Photobiol.*, 1991, 54:197-203). UV-induced free radical generation in skin has been demonstrated (Peak et al., *Photochem. Photobiol.*, 1991, 54:197-203; and Norins, A.L., *J. Invest. Dermatol.*, 1962, 39:445-448). In addition, some enzymes which protect against oxidative damage, such as superoxide dismutase and catalase, are depleted after

UV exposure (Pence, B.C. and Naylor, M.F., *J. Invest. Dermatol.*, 1990 95:213-216; Maeda et al., *Photochem. Photobiol.*, 1991, 54:737-740; Shindo, Y and Hashimoto, T., *J. Dermatol. Sci.*, 1997, 14:225-232), and antioxidants that scavenge free radicals have demonstrated protection against UV (DeRios et al., *J. Invest. Dermatol.*, 1975, 70:123-125; and Bissett et al., *J. Soc. Cosmet. Chem., 1992,* 43:85-92). Investigators have recently demonstrated elastin mRNA production in response to free radicals generated using a xanthine and xanthine oxidase system *in vitro*, providing evidence for the role of oxidative stress in the generation of solar elastosis (Kawaguchi et al., *Free Radical Biol. Med.*, 1997, 23:162-165).

A transgenic hairless mouse model has now been developed which expresses a full length or truncated human elastin promoter/reporter gene. These transgenic hairless mice express human elastin promoter activity in a tissue-specific and developmentally regulated manner. Not only can quantitative data be obtained in these mice or fibroblasts derived therefrom after only a single exposure to ultraviolet radiation, but these hairless mice can also be used in long term phototoxicity studies. A single exposure to UVB in transgenic hairless mice having a truncated elastin promoter resulted in about a 20 to 30 fold increase in elastin activity as compared to an 8-fold increase reported for prior art models expressing the full length promoter. Accordingly, this transgenic hairless mouse and fibroblasts derived from this hairless mouse are useful as *in vivo* and *in vitro* models to study cutaneous photoaging and in the identification of agents which may protect against photodamage.

Further, reactive oxygen species are also believed to stimulate elastin production at the promoter level in fibroblasts derived from these mice. Accordingly, the present invention also relates to an *in vitro* system and method for

identifying agents capable of protecting against oxidative damage via a mouse fibroblast culture derived from a transgenic hairless mouse capable of expressing a full length or truncated human elastin promoter and a means for generating reactive oxygen species within the mouse fibroblast cultures.

Summary of the Invention

An object of the present invention is to provide a transgenic hairless mouse capable of expressing a full length or truncated human elastin promoter.

Another object of the present invention is to provide mouse fibroblast cultures derived from a transgenic hairless mouse capable of expressing a full length or truncated human elastin promoter.

Another object of the present invention is to provide methods of identifying compounds capable of inhibiting cutaneous photodamage using either the transgenic hairless mouse or fibroblasts derived from these mice.

Another object of the present invention is to provide an *in vitro* system for identifying agents capable of inhibiting or preventing oxidative damage comprising a mouse fibroblast culture derived from a transgenic hairless mouse capable of expressing a full length or truncated human elastin promoter and a means for generating reactive oxygen species within the mouse fibroblast culture.

Yet another object of the present invention is to provide a method of identifying agents capable of inhibiting or preventing oxidative damage using this *in vitro* system.

Detailed Description of the Invention

In the present invention, a transgenic hairless mouse model has been developed which permits the investigation of human elastin promoter activity in response to ultraviolet irradiation both *in vivo* by direct irradiation of mouse skin, and *in vitro* by irradiation of dermal fibroblasts grown from

skin explants of these mice. In a preferred embodiment the hairless mouse used in the production of these transgenic mice is of the strain Crl:SKH1-hrBR (Charles River) as this hairless strain of mice is well characterized and used routinely in preclinical dermatological and photobiological research. The transgenic hairless mice of the present invention are capable of expressing a full length or truncated elastin promoter. By "truncated human elastin promoter" it is meant a human elastin promoter shorter than the full length 5.2 kb human elastin promoter such as pEP62, pEP35, pEP10, pEP27, and pEP6 (Kahari et al., *J. Biol. Chem.*, 1990, 265(16):9485-9490) which is activated by UV. In a preferred embodiment, the truncated elastin promoter is pEP6. It is also preferred that the promoter be linked to a reporter gene such as the chloramphenicol acetyltransferase reporter gene (CAT) for ease in detecting activity of the full length or truncated promoter.

Other *in vivo* models of photoaging require numerous treatments over long periods of time to demonstrate a measurable effect. For example, experimentally produced elastosis in mice was first produced by Sams et al. using very large amounts of ultraviolet radiation (*J. Invest. Dermatol.*, 1964, 43:467-471). In these studies, one group of mice received 1,040 human minimal erythema doses (MEDs) over 3 months from a bank of fluorescent tubes, while another group received 13,000 MEDs given over 52 weeks in 260 treatments. Elastosis was demonstrated by histochemical staining for elastin and, in irradiated mice, demonstrated an increased elastin staining. Since this initial report, a number of researchers have used murine models of cutaneous photoaging evaluating the production of dermal elastosis (Sams et al., *J. Invest. Dermatol.*, 1964, 43:467-471; Nakamura, K. and Johnson, W.C., *J. Invest. Dermatol.*, 1968, 51:253-258; Berger et al., *Arch. Dermatol. Res.*, 1980, 269:39-49; Kligman, L.H., *Arch. Dermatol. Res.*, 1982, 272:229-238; Kligman et al., *J.*

Invest. Dermatol., 1982, 78:181-189; Poulsen et al., *Br. J. Dermatol.*, 1984, 110:531-538; Kligman et al., *J. Invest. Dermatol.*, 1985, 84:272-276; Bissett et al., *Photochem. Photobiol.*, 1987,, 1987 46:367-376; Bissett et al., *Photochem. Photobiol.*, 1989, 50:763-769; Wulf et al., *Photodermatology* 6:44-51, 1989; Kligman, L.H. and Sayre, R.M., *Photochem. Photobiol.*, 1991, 53:237-242; and Moran, M. and Granstein, R.D., *J. Invest. Dermatol.*, 1994, 103:797-800). The number of treatments with ultraviolet radiation in these studies ranges from 36 to 260 given over 13 to 62 weeks.

A homozygous line of transgenic mice expressing the 5.2-kb human elastin promoter linked to a CAT reporter gene has been disclosed (Hsu-Wong et al., *J. Biol. Chem.*, 1994, 269:18072-18075). U.S. Patent 5,648,061 discloses the use of this transgenic mouse model to investigate human elastin promoter activity in response to ultraviolet irradiation both *in vivo* by direct irradiation of mouse skin, and *in vitro* by irradiation of dermal fibroblasts grown from skin explants. These mice express the human elastin promoter in a tissue-specific and developmentally regulated manner. Further, a dose-response relationship for elastin promoter activity after only a single dose of UV has been observed. In these mice a single dose of UVB (491.4 mJ/cm^2) resulted in up to an 8.5-fold increase in promoter activity, while a more modest 1.8-fold increase was measured with UVA (38.2 J/cm^2). However, mice four or five days old must be used since at this age, visible hair growth is not yet present.

Further, experiments with UVA treatment in these mice, and more particularly fibroblasts derived from these mice, require addition of 8-methoxypsoralen prior to UVA exposure to achieve a significant increase in elastin promoter activity. The combination of 8-methoxypsoralen (8-MOP) and UVA is referred to routinely in the art as PUVA. Treatment of skin diseases with PUVA results in clinical alterations in

treated skin similar to those observed in chronically photodamaged skin. PUVA-treated patients develop non-melanoma skin cancers, pigmentary alterations and wrinkling characteristics of sun-induced changes. Fibroblast cultures derived from the mice of Hsu-Wong et al. treated with 8-MOP or UVA alone exhibited no significant change in CAT activity as compared to untreated controls. However, PUVA-treated cell cultures demonstrated 2.6-, 13.2- and 2.0-fold increases in CAT activity in response to 1 J/cm^2 of UVA with 8-MOP doses of 0.3, 1.0, and 3.0 $\mu g/ml$ of 8-MOP, respectively.

In the hairless mice of the present invention, not only is a quantifiable increase in elastin promoter activity in UVB-treated mice observed after a single dose of UVB, but these mice can also be used in long term phototoxicity studies. Further, a 20 to 30 fold increase in promoter activity was observed in mice of the present invention expressing a truncated human elastin promoter following a single dose of UVB, thus demonstrating that transgenic hairless mice capable of expressing a truncated elastin promoter provide a more sensitive model as compared to prior art mice expressing the full length promoter. With this increase in sensitivity to UV, it is believed that application of psoralen to fibroblasts and/or mice will no longer be required in experiments investigating UVA effects.

The present invention also relates to methods of identifying compounds capable of inhibiting cutaneous photodamage with this transgenic hairless mouse model. In one embodiment a test compound is applied to the skin of a transgenic hairless mouse capable of expressing a full length or truncated human elastin promoter. The transgenic hairless mouse is then exposed to ultraviolet radiation, either solar simulating, UVB or UVA, and human elastin promoter activity in the mouse is determined. The human elastin promoter activity is then compared to that in control transgenic hairless mice also exposed to an equivalent dose of

ultraviolet radiation which were not treated with the test compound to determine whether or not the test compound provided protection against the ultraviolet radiation. In another embodiment, fibroblast cells derived from a transgenic mouse capable of expressing a full length or truncated human elastin promoter are treated with a test compound. The treated fibroblast cells are then exposed to solar simulating, UVB or UVA radiation and human elastin promoter activity in the fibroblast cells is determined. This activity is compared to control fibroblast cells from the transgenic mice exposed to the same dose of solar simulating, UVB or UVA radiation but which were not treated with the test compound to determine if the test compound provided protection against the exposure.

Oxidative damage is also believed to play a role in dermal damage from UV radiation. Thus, the generation of photoaging, clinically evident as wrinkling and sagging of skin, may result more from free radical-induced mechanisms than UV-induced skin cancers which originate in the epidermis. Evidence for this includes the greater sensitivity of fibroblasts to free radical-induced damage as compared to keratinocytes (Applegate, L.A. and Frenk, E. *Photodermatol. Photoimmunol. Photomed.*, 1995, 11:95-101; Moysan et al., *Photodermatol. Photoimmunol. Photomed.*, 1995, 11:192-197; Masaki, H. and Sakurai, H. *J., Dermatol. Sci.*, 1997, 14:207-216), and the fact that circulating inflammatory cells which produce free radicals course through the dermis and less frequently invade the epidermis. Also the longer wavelengths of UV, which produce less direct DNA damage (Setlow, R.B., *Science*, 1966, 153:379-386) but may exert their deleterious effects mainly through oxidative mechanisms, penetrate more deeply into skin, depositing much of their energy in the dermis. Thus, free radical mechanisms of damage may be the primary means by which UVA-induced photoaging takes place.

A number of effective sunscreens for blocking UVB are currently on the market, and increasing amounts of UVA

protection are being incorporated into sunscreens to obtain higher sun protection factors. Further improvements are likely to result from incorporating effective free radical scavengers into currently available sunscreens. Accordingly, there is a need for a system of identifying agents which inhibit or prevent oxidative damage from the sun.

Generation of reactive oxygen species via a hypoxanthine and xanthine oxidase system in dermal fibroblasts derived from transgenic mice expressing a full length human elastin promoter results in a measurable increase in elastin promoter activity. Further, this increase can be eliminated by the addition of catalase, an enzyme known to protect against oxidative damage. Accordingly, incorporation of a means for generating reactive oxygen species such as a hypoxanthine and xanthine oxidase system within mouse fibroblast cultures derived from the transgenic hairless mice of the present invention is believed to provide a sensitive system for evaluating agents which may prevent oxidative damage. Using this system, agents which may protect against the oxidative damage resulting from UV exposure may be rapidly screened, and promising candidates identified for further study and eventual incorporation into sunscreens.

Test agents suspected of providing protection against oxidative damage can be added to the hairless mouse fibroblast culture prior to addition of the means for generation of reactive oxygen species. The means for generating reactive oxygen species is then added and human elastin promoter activity is determined in the mouse fibroblast culture after a selected time period. The time period for determination of human elastin promoter can be selected in accordance with routine experiments wherein optimum time span for incubation of fibroblasts, derived from the skin of the transgenic mice, with a hypoxanthine and xanthine oxidase system is determined. More specifically, optimum time span for incubation is determined by exposing cells to a hypoxanthine and xanthine

oxidase system for increasing amounts of time, and determining promoter activity at various times throughout a 24 hour incubation. Optimum time is determined as the point at which CAT activity peaks.

In a preferred embodiment, elastin promoter activity is determined by measuring expression of the reporter gene, i.e. the CAT activity, in the hairless mouse fibroblast culture. Human elastin promoter activity in the hairless mouse fibroblast culture exposed to the test agent is then compared to elastin promoter activity in a control hairless mouse fibroblast culture not exposed to the test agent but still exposed to the means for generating reactive oxygen species. Agents providing protection against oxidative damage are identified as those test agents which decrease human elastin promoter activity in the hairless mouse fibroblast culture exposed to the test agent and the means for generating reactive oxygen species as compared to the control hairless mouse fibroblast culture.

The following nonlimiting examples are provided to further illustrate the present invention.

Examples

Example 1: Transgenic mice expressing the human elastin promoter

Homozygous lines of hairless transgenic mice of the strain Crl:SKH1-hrBR (Charles River) expressing either the full length 5.2-kb human elastin promoter linked to a CAT reporter gene or the truncated human elastin promoter, pEP6 (Kahari et al., *J. Biol. Chem.*, 265(16):9485-9490, 1990), linked to a CAT reporter gene were produced in accordance with known methods for production of transgenic mice.

Example 2: Fibroblast Cultures Expressing the Human Elastin Promoter

Fibroblasts derived from the skin of homozygous lines of transgenic hairless mice expressing either the full length 5.2-kb human elastin promoter or the truncated elastin promoter pEP6 (Kahari et al., *J. Biol. Chem.*, 1990, 265(16):9485-9490), linked to a CAT reporter gene which enables measurement of elastin promoter activation, as previously described (Bernstein et al., *J Invest Dermatol*, 1995, 105, 269-273; and Bernstein et al., *Photochem Photobiol*, 1996, 64:369-74) are utilized. Although phenotypically normal, these mice express the human elastin promoter when assayed for CAT activity (Hsu-Wong et al., *J. Biol. Chem.*, 1994, 269: 18072-18075; Bernstein et al., *J Invest Dermatol*, 1995, 105, 269-273; and Bernstein et al., *Photochem Photobiol*, 1996, 64:369-74).

Fibroblast cultures are established from the skin of these hairless transgenic mice by explanting tissue specimens onto plastic tissue culture dishes and allowing cells to migrate to the area of the dish surrounding the explants. The primary cultures are maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and antibiotics, at 37°C. After exposure to ultraviolet radiation, the cells are incubated in DME medium supplemented with 10% fetal calf serum for 24 hours, then harvested for determination of CAT activity as described in Example 4.

Example 3: Exposure of fibroblast cultures to free radicals generated by hypoxanthine/xanthine oxidase

DMEM with 10% FCS is removed, cells are rinsed in phosphate buffered saline (PBS), and DMEM is replaced without the addition of FCS. Both 500 μM hypoxanthine (Sigma Chemical Co., St. Louis, MO) and 80 mU/ml xanthine oxidase (Sigma

Chemical Co., St. Louis, MO) are then added to fibroblast cultures and incubated at 37°C for a selected time period. These concentrations of hypoxanthine and xanthine oxidase were selected based on previous work by Mitchell et al. (*Biochemistry* 29:2802-2807, 1990). The time for incubation of cells with hypoxanthine/xanthine oxidase can be selected by exposing cells to hypoxanthine/xanthine oxidase for 15, 30, 60, 90 and 120 minutes and determining CAT activity as outlined in Example 4.

After exposure to hypoxanthine/xanthine oxidase, cells are rinsed in PBS and incubated in DMEM with FCS for the time in which maximal promoter activation is determined to occur after exposure to hypoxanthine/xanthine oxidase. Control cells are treated in an identical fashion without the addition of hypoxanthine/xanthine oxidase.

In addition to hypoxanthine/xanthine oxidase treatment alone, cells are also treated with hypoxanthine/xanthine oxidase plus 10,000 U/ml of catalase (Sigma Chemical Co., St. Louis, MO) co-incubated for a selected time, and harvested as outlined above. Fibroblasts from the hairless mice representing the same litter are used for any given experiment. Four dishes of cells are used for each experimental condition (control, hypoxanthine/xanthine oxidase, and hypoxanthine/xanthine oxidase+catalase), and experiments are repeated in duplicate, yielding a total of eight values for each experimental condition.

The effect of hypoxanthine/xanthine oxidase and hypoxanthine/xanthine oxidase+catalase on cell viability is determined using the trypan blue (Sigma Chemical Co., St. Louis, MO) exclusion method (Ausubel *et al.*, Short Protocols in Molecular Biology, John Wiley & Sons, Inc., 2nd ed., New York, 1992, p.11-24), and a paired t-test analysis is performed for statistical evaluation of the data.

Example 4: CAT Assay

To measure the expression of the human elastin promoter/CAT reporter gene construct in the skin of transgenic hairless mice and in fibroblast cultures established from these animals, CAT activity is determined. For extraction of the CAT from skin, the specimens are homogenized in 0.25 Tris-HCl, pH 7.5, using a tissue homogenizer (Brinkmann Instruments, Inc., Westbury, NY). The homogenates are centrifuged at 10,000 X g for 15 minutes at 4°C and the protein concentration in the supernatant determined by a commercial protein assay kit (Bio-Rad Laboratories, Richmond, CA). Aliquots of the supernatant containing 100 μg of protein are used for assay of CAT activity by incubation with [^{14}C] chloramphenicol in accordance with well-known procedures. The acetylated and non-acetylated forms of radioactive chloramphenicol are separated by thin-layer chromatography and CAT activity is determined by the radioactivity in the acetylated forms as a percent of the total radioactivity in each sample.

Example 5: UV Sources

For administration of UVB radiation, a closely spaced array of seven Westinghouse FS-40 sunlamps is used which delivers uniform irradiation at a distance of 35 cm. Irradiating with UVA is performed using seven Sylvania FR40T12 PUVA lamps in the above mentioned array, filtered through window glass of 2 mm thickness to remove wavelengths below 320 nm. The energy output at 35 cm is measured with a Solar Light model 3D UVA and UVB detector (Solar Light Company, Philadelphia, PA). The output of FX-40 sunlamps is 23.4 units/hour of UVB at 38 cm, where each unit is equivalent to 21 mJ/cm^2 of erythema effective energy. The output for FR40T12 PUVA lamps filtered through window glass is 2.02 mW/cm^2, with no detectable UVB radiation.

A Multiport Solar Simulator (Solar Light Company, Philadelphia, PA) containing a xenon arc lamp filtered through a Schott WG 320 filter (Schott Glaswerke, Mainz, Germany) is used to administer solar simulating radiation (SSR). The output of the solar simulator is measured by means of a 3D UV meter (Solar Light Company) and displayed as human minimal erythema doses (MEDs). The emission spectrum of the lamp closely simulates solar radiation reaching the earth's surface.

Example 6: Irradiation

Mice are placed under the center of the light array and restrained with adhesive tape, exposing their dorsal surfaces to the ultraviolet radiation at a distance of 35 cm from the fluorescent tubes. For the Multiport Solar Simulator, light guides from the solar simulator are placed in light contact with the dorsal surface of the mice, which are restrained to prevent movement while SSR is administered. Untreated control mice are restrained in a similar manner.

Fibroblast cultures as described above are exposed for 5, 10, 20, 40 and 80 seconds of UVB corresponding to doses of 0.7, 1.4, 2.7, 5.5 and 10.9 mJ/cm^2, respectively. Cultures are exposed to UVA for 2.3, 4.6, 9.2 and 18.4 minutes corresponding to doses of 0.3, 0.6, 1.1 and 2.2 J/cm^2. To prevent light absorption by tissue culture medium, just prior to irradiation, tissue culture medium is removed from cells and replaced with a thin layer of phosphate buffered saline (PBS) sufficient to cover the cells. Control unirradiated cells are also placed in PBS. Medium is replaced in all dishes immediately after the last light dose is administered. Only fibroblasts from mice in the same litters are used for any given experiment and utilized in the first few passages. Two dishes of cells are used for each time point.

What is claimed is:

1. A transgenic hairless mouse capable of expressing a full length or truncated human elastin promoter.

2. A mouse fibroblast culture derived from the transgenic hairless mouse of claim 1.

3. A method of identifying compounds capable of inhibiting cutaneous photodamage comprising:

(a) applying a test compound to skin of the transgenic hairless mouse of claim 1;

(b) exposing the transgenic mouse to UVB radiation, UVA radiation, or solar simulating radiation; and

(c) measuring human elastin promoter activity in the transgenic hairless mouse, wherein a compound which decreases the measured human elastin promoter activity as compared to control transgenic hairless mice inhibits cutaneous photodamage.

4. A method of identifying compounds capable of inhibiting cutaneous photodamage comprising:

(a) contacting the mouse fibroblast culture of claim 2 with a test compound;

(b) exposing the mouse fibroblast culture to UVB radiation, UVA radiation or solar simulating radiation; and

(c) measuring human elastin promoter activity in the mouse fibroblast culture, wherein a compound which decreases the measured human elastin promoter activity as compare to control mouse fibroblast culture inhibits cutaneous photodamage.

5. An *in vitro* system for identifying agents capable of inhibiting or preventing oxidative damage comprising:

the mouse fibroblast culture of claim 2; and

a means for generating reactive oxygen species within the mouse fibroblast culture.

6. A method for identifying agents capable of inhibiting or preventing oxidative damage comprising:

adding a test agent suspected of providing protection against oxidative damage to the mouse fibroblast culture of claim 2;

adding a means for generation of reactive oxygen species to the mouse fibroblast culture;

determining human elastin promoter activity in the mouse fibroblast culture exposed to the test agent after a selected time period; and

comparing the determined human elastin promoter activity in the mouse fibroblast culture exposed to the test agent to human elastin promoter activity in a control fibroblast culture wherein a decrease in the determined human elastin promoter activity is indicative of the test agent inhibiting or preventing oxidative damage.

Docket No.
BERN-0050

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

An In Vivo and In Vitro Model for Cutaneous Photoaging and Oxidative Damage

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on **22 February 2000** as United States Application No. or PCT International Application Number **PCT/US00/04703**

and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Not Claimed
(Number)	(Country)	(Day/Month/Year Filed)	☐
(Number)	(Country)	(Day/Month/Year Filed)	☐
(Number)	(Country)	(Day/Month/Year Filed)	☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)	(Filing Date)
60/120,269	**February 24, 1999**

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*



Send Correspondence to:

Direct Telephone Calls to: *(name and telephone number)*
Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor **Eric F. Bernstein**
Sole or first inventor's signature Date 11/21/01
Residence **Wynnewood, Pennsylvania**
Citizenship **US**
Post Office Address **1321 Grennox Road** PA
Wynnewood, Pennsylvania 19096

Full name of second inventor, if any
Second inventor's signature Date
Residence
Citizenship
Post Office Address